×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IMGN – immunogen, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IMGN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/5
06:30 am
imgn
FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer
Low
Report
FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer
12/4
07:00 pm
imgn
IMMUNOGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ImmunoGen, Inc. - IMGN
Low
Report
IMMUNOGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ImmunoGen, Inc. - IMGN
12/4
01:35 pm
imgn
Are You Looking for a Top Momentum Pick? Why ImmunoGen (IMGN) is a Great Choice [Yahoo! Finance]
Low
Report
Are You Looking for a Top Momentum Pick? Why ImmunoGen (IMGN) is a Great Choice [Yahoo! Finance]
12/4
08:13 am
imgn
ImmunoGen, Inc. (NASDAQ: IMGN) had its "neutral" rating re-affirmed by analysts at Piper Sandler. They now have a $31.00 price target on the stock, up previously from $24.00.
Low
Report
ImmunoGen, Inc. (NASDAQ: IMGN) had its "neutral" rating re-affirmed by analysts at Piper Sandler. They now have a $31.00 price target on the stock, up previously from $24.00.
12/2
05:57 am
imgn
ImmunoGen, Inc. (NASDAQ: IMGN) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
Low
Report
ImmunoGen, Inc. (NASDAQ: IMGN) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
12/1
04:30 pm
imgn
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/1
02:46 pm
imgn
Immunogen's AbbVie Deal: Key Insights For Investors And Traders [Seeking Alpha]
Low
Report
Immunogen's AbbVie Deal: Key Insights For Investors And Traders [Seeking Alpha]
12/1
02:28 pm
imgn
ImmunoGen, Inc. (NASDAQ: IMGN) had its "equal weight" rating re-affirmed by analysts at Barclays PLC.
Low
Report
ImmunoGen, Inc. (NASDAQ: IMGN) had its "equal weight" rating re-affirmed by analysts at Barclays PLC.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/5
09:09 pm
imgn
Form 4 ImmunoGen, Inc. For: Nov 30 Filed by: Coen Stacy Ann
Low
Report
Form 4 ImmunoGen, Inc. For: Nov 30 Filed by: Coen Stacy Ann
12/5
09:07 pm
imgn
Form 4 ImmunoGen, Inc. For: Nov 30 Filed by: Peterson Kristine
Low
Report
Form 4 ImmunoGen, Inc. For: Nov 30 Filed by: Peterson Kristine
12/1
07:32 pm
imgn
Form 4 ImmunoGen, Inc. For: Nov 29 Filed by: Wingrove Theresa
Low
Report
Form 4 ImmunoGen, Inc. For: Nov 29 Filed by: Wingrove Theresa
12/1
03:27 pm
imgn
Form 144 ImmunoGen, Inc. Filed by: Coen Stacy Ann
Low
Report
Form 144 ImmunoGen, Inc. Filed by: Coen Stacy Ann
11/30
05:11 pm
imgn
Form 144 ImmunoGen, Inc. Filed by: Peterson Kristine
Low
Report
Form 144 ImmunoGen, Inc. Filed by: Peterson Kristine
11/30
05:10 pm
imgn
Form 144 ImmunoGen, Inc. Filed by: Wingrove Theresa
Low
Report
Form 144 ImmunoGen, Inc. Filed by: Wingrove Theresa
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/24
ImmunoGen, Inc. (NASDAQ: IMGN) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating.
34.3%
11/1 Q3/2019 9/30/2019 EPS -0.150 ZacksConsensus -0.190 ActVsEst 0.040 - Beat 27.7%
2/14 Form 8-K ImmunoGen, Inc. For: Feb 14 21.4%
12/17 ImmunoGen Announces Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer 15.5%
5/4 Immunogen Inc. (IMGN) CEO Mark Enyedy on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 14.2%
8/5 Form 8-K/A IMMUNOGEN INC For: Jun 26 11.6%
10/18 ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2019 Operating Results 11.0%
3/23 ImmunoGen, Inc. (NASDAQ: IMGN) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. 10.4%
12/19 ImmunoGen, Inc. (NASDAQ: IMGN) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 10.3%
11/5 How Many ImmunoGen, Inc. (NASDAQ:IMGN) Shares Do Institutions Own? [Yahoo! Finance News] 10.2%
11/1 Q3/2019 9/30/2019 EPS -0.150 ZacksConsensus -0.190 ActVsEst 0.040 - Beat 27.7%
2/14 Form 8-K ImmunoGen, Inc. For: Feb 14 21.4%
12/17 ImmunoGen Announces Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer 15.5%
5/4 Immunogen Inc. (IMGN) CEO Mark Enyedy on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 14.2%
8/5 Form 8-K/A IMMUNOGEN INC For: Jun 26 11.6%
10/18 ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2019 Operating Results 11.0%
3/23 ImmunoGen, Inc. (NASDAQ: IMGN) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. 10.4%
12/19 ImmunoGen, Inc. (NASDAQ: IMGN) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 10.3%
11/5 How Many ImmunoGen, Inc. (NASDAQ:IMGN) Shares Do Institutions Own? [Yahoo! Finance News] 10.2%
TOP News Decliners
5/15
ImmunoGen Provides Regulatory Update on Mirvetuximab Soravtansine Monotherapy in Ovarian Cancer
-32.1%
9/30 Form 8-K ImmunoGen, Inc. For: Sep 29 -19.3%
5/1 Q1/2020 3/31/2020 EPS -0.170 ZacksConsensus -0.150 ActVsEst (0.020) - Miss -16.5%
11/6 ImmunoGen to Present New Data on IMGN632 at 61st ASH Annual Meeting -14.3%
3/11 Form 10-K ImmunoGen, Inc. For: Dec 31 -14.2%
1/23 Form 8-K ImmunoGen, Inc. For: Jan 22 -12.0%
5/16 ImmunoGen, Solid Biosciences and Insys lead Wednesday’s biotech losers [MarketWatch] -10.5%
2/14 Form 8-K ImmunoGen, Inc. For: Feb 12 -9.8%
12/20 Form 8-K ImmunoGen, Inc. For: Dec 19 -8.7%
3/18 ImmunoGen, Inc. (NASDAQ: IMGN) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -7.8%
9/30 Form 8-K ImmunoGen, Inc. For: Sep 29 -19.3%
5/1 Q1/2020 3/31/2020 EPS -0.170 ZacksConsensus -0.150 ActVsEst (0.020) - Miss -16.5%
11/6 ImmunoGen to Present New Data on IMGN632 at 61st ASH Annual Meeting -14.3%
3/11 Form 10-K ImmunoGen, Inc. For: Dec 31 -14.2%
1/23 Form 8-K ImmunoGen, Inc. For: Jan 22 -12.0%
5/16 ImmunoGen, Solid Biosciences and Insys lead Wednesday’s biotech losers [MarketWatch] -10.5%
2/14 Form 8-K ImmunoGen, Inc. For: Feb 12 -9.8%
12/20 Form 8-K ImmunoGen, Inc. For: Dec 19 -8.7%
3/18 ImmunoGen, Inc. (NASDAQ: IMGN) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -7.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: